TABLE 2.

Susceptibility of baseline isolates to protease inhibitors

Compound	No. of baseline isolates tested	Change (n-fold) in IC50 compared to WT		No. (%) with ≥2.5-fold change
		Median	Range
Lopinavir	45	5.9	0.4-167	30a (67)
Ritonavir	45	17.5	0.3-316	34 (76)
Indinavir	45	10.6	0.4-171	28 (62)
Nelfinavir	45	19.5	0.5-228	33 (73)
Amprenavir	35	2.4	0.4-49	17 (49)
Saquinavir	45	2.2	0.2-462	20 (44)

^aGreater than 10-fold reduction in LPV susceptibility was observed in 19 of 45 baseline isolates.